Two High-Yield Dividend Stocks Offering Up to 7% Returns
Investors seeking reliable passive income are turning to dividend stocks, with Pfizer emerging as a standout. The pharmaceutical giant, known for its COVID-19 vaccine, is now pivoting to oncology and weight-loss drugs after its $43 billion acquisition of Seagen. Management projects $10 billion in adjusted revenue from Seagen's pipeline by 2030, offsetting patent expirations.
Dividend yields of 7% often raise eyebrows, but Pfizer's strategic moves and robust pipeline suggest sustainability. The market watches closely as the company navigates patent cliffs and tariff pressures while expanding its drug portfolio.